|Table of Contents|

Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients



Research Field:
Publishing date:



Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients


CHEN Yunlong LIU Chuan LIU Xiaoyan GUO Zhinian WENG Xiangui WANG Rong WANG Jiang

Department of Cardiology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China


coronary heart disease diabetes mellitus lipoprotein-associated phospholipase A2 hemoglobin A1c


ObjectiveTo explore the correlation of circulating lipoproteinassociated phospholipase A2 (LpPLA2) and hemoglobin A1c (HbA1c) levels with the severity of coronary artery stenosis in patients with type 2 diabetes mellitus (T2DM). MethodsA total of 241 inpatients with suspected coronary artery disease (CHD) admitted in our department between July, 2017 and December, 2017 were enrolled in this study. According to the findings in coronary angiography, the patients were divided into CHD, T2DM, CHD with T2DM and healthy control groups. The patients were also stratified according to their left ventricular ejection fraction (LVEF) into LVEF <50% group and LVEF≥50% group. For all the participants, circulating HbA1c level was determined with chemiluminescence detection and LpPLA2 level with enzymelinked immunosorbent assay (ELISA). ResultsLpPLA2 level was significantly higher in diabetic patients with CHD than in those with T2DM and the healthy control subjects (P<0.05). The diabetic patients with CHD also showed a significantly higher level of HbA1c than those with CHD and the control subjects (P<0.05). Multivariate linear regression analysis showed that LpPLA2 (r=0.189, P<0.05) and HbA1c (r=0.138, P<0.05) levels were both positively correlated with the severity of coronary stenosis (Gensini score). Multivariate logistic regression analysis identified LpPLA2 (OR=1.012, P<0.05) and HbA1c (OR=0.097, P<0.05) as independent risk factors for coronary stenosis. The patients with a LVEF <50% had a significantly higher LpPLA2 level than those with a LVEF ≥50% (P<0.05), but their HbA1c level did not differ significantly (P>0.05). ConclusionIn diabetic patients with CHD, LpPLA2 and HbA1c levels are positively correlated with the severity of coronary artery stenosis, and the combined detection of LpPLA2 and HbA1c can be clinically informative for predicting the severity of coronary artery stenosis.


[1]SOFOGIANNI A, ALKAGIET S, TZIOMALOS K. Lipoproteinassociated phospholipase A2 and coronary heart disease[J]. Curr Pharm Des, 2018, 10. DOI: 10.2174/1381612 824666180111110550.[Epub ahead of print]
[2]GARG P K, MCCLELLAND R L, JENNY N S, et al. Lipoproteinassociated phospholipase A2 and risk of incident cardiovascular disease in a multiethnic cohort: The multi ethnic study of atherosclerosis[J]. Atherosclerosis, 2015, 241(1): 176-182. DOI: 10.1016/j.atherosclerosis.2015.05.006.
[3]LI D, ZHAO L, YU J, et al. Lipoproteinassociated phospholipase A2 in coronary heart disease: review and metaanalysis[J]. Clin Chim Acta, 2017, 465: 22-29. DOI: 10.1016/j.cca.2016.12.006.
[4]BALLANTYNE C M, HOOGEVEEN R C, BANG H, et al. Lipoproteinassociated phospholipase A2, highsensitivity Creactive protein, and risk for incident coronary heart disease in middleaged men and women in the atherosclerosis risk in communities (ARIC) study[J]. Circulation, 2004, 109(7): 837-842. DOI: 10.1161/01.CIR.0000116763.91992.F1.
[5]DANIELS L B, LAUGHLIN G A, SARNO M J, et al. Lipoproteinassociated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study[J]. J Am Coll Cardiol, 2008, 51(9): 913-919. DOI: 10. 1016/j.jacc.2007.10.048.
[6]YANG L, LIU Y, WANG S, et al. Association between LpPLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res, 2017, 45(1): 159-169. DOI: 10.1177/030 0060516678145.
[7]BENDERLY M, SAPIR B, KALTERLEIBOVICI O, et al. Lipoproteinassociated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease[J]. Biomarkers, 2017, 22(34): 219-224. DOI: 10.3109/1354750X.2016.1171910.
[8]ARSENAULT B J, KOHLI P, LAMBERT G, et al. Emerging cardiovascular disease biomarkers and incident diabetes mellitus risk in statintreated patients with coronary artery disease (from the treating to new targets [TNT]study)[J]. Am J Cardiol, 2016, 118(4): 494-498. DOI: 10.1016/j.amjcard.2016.05.044.
[9]MAYER O J R, SEIDLEROVá J, FILIPOVSKY J, et al. Unexpected inverse relationship between impaired glucose metabolism and lipoproteinassociated phospholipase A2 activity in patients with stable vascular disease[J]. Eur J Intern Med, 2014, 25(6): 556-560. DOI: 10.1016/j.ejim.2014.05.010.
[10]GARG S, MADHU S V, SUNEJA S. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type2 diabetes mellitus[J]. Indian J Med Res, 2015, 141(1): 107-114. DOI: 10.4103/09715916.154512.
[11]SEYFARTH J, REINEHR T, HOYER A, et al. Lipoproteinassociated phospholipase A2 activity in obese adolescents with and without type 2 diabetes[J]. J Inherit Metab Dis, 2018, 41(1): 73-79. DOI: 10.1007/s1054501701000.
[12]Kotani K.Plasma lipoproteinassociated phospholipase A2 levels correlated with the cardioankle vascular index in longterm type 2 diabetes mellitus patients[J]. Int J Mol Sci, 2016, 17(5): pii: E634. DOI: 10.3390/ijms17050634.
[13]JIANG J, ZHAO L, LIN L, et al. Postprandial blood glucose outweighs fasting blood glucose and HbA1c in screening coronary heart disease[J]. Sci Rep, 2017, 7(1): 14212. DOI: 10.1038/s4159801714152y.
[14]ERTEM A G, BAGˇBANCI H, KILI H, et al. Relationship between HbA1c levels and coronary artery severity in nondiabetic acute coronary syndrome patients[J]. Turk Kardiyol Dern Ars, 2013, 41(5): 389-395.
[15]WHITE H D, SIMES J, STEWART R A, et al. Changes in lipoproteinassociated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the longterm intervention with pravastatin in ischemic disease study[J]. J Am Heart Assoc, 2013, 2(5): e000360. DOI: 10.1161/JAHA.113.000360.
[16]SCHAEFER E J, MCNAMARA J R, ASZTALOS B F, et al. Effects of atorvastatin versus other statins on fasting and postprandial Creactive protein and lipoproteinassociated phospholipase A2 in patients with coronary heart disease versus control subjects[J]. Am J Cardiol, 2005, 95(9): 1025-1032. DOI: 10.1016/j.amjcard.2005.01.023.
[17]STABILITY INVESTIGATORS, WHITE H D, HELD C, et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med, 2014, 370(18): 1702-1711. DOI: 10.1056/NEJMoa1315878.
[18]O’DONOGHUE M L, BRAUNWALD E, WHITE H D, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLIDTIMI 52 randomized clinical trial[J]. JAMA, 2014, 312(10): 1006-1015. DOI: 10.1001/jama.2014.11061.


Last Update: 2018-07-03